BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 29
• 30

• New Twist on Treatment of Foot Pain, University of Genoa Study

  December 2, 2008

   · 

  1 min read
• Business

  Adeona Pharmaceuticals and National Neurovision Research Institute (NNRI) Collaborate to Test Flupirtine for Retinitis Pigmentosa

  December 2, 2008

   · 

  1 min read
• Job Trends

  Targeted Genetics Corporation Realigns Product Development Priorities and Cuts Costs by Personnel Reductions; Salary Deferrals; Reductions

  December 2, 2008

   · 

  8 min read
• Job Trends

  InSite Vision Announces Corporate Restructuring To Focus on Growth Opportunities and Conserve Resources

  December 2, 2008

   · 

  5 min read
• Drug Development

  S*Bio Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis

  December 2, 2008

   · 

  3 min read
• WuXi PharmaTech Co., Ltd. Will Focus U.S. Operations on Laboratory Testing Services; U.S. Biologics Manufacturing Operations to be Discontinued

  December 2, 2008

   · 

  6 min read
• Biotech Bay

  Arcadia Biosciences, Inc. Receives $3.6 Million USAID Grant to Develop Improved Crops in India

  December 2, 2008

   · 

  1 min read
• Drug Development

  TargeGen, Inc. Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 American Society of Hematology Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

  December 2, 2008

   · 

  1 min read
• Deals

  Ethicon, Inc. Completes Divestiture of Professional Wound Care Business to One Equity Partners

  December 2, 2008

   · 

  3 min read
• Drug Development

  Vanda Pharmaceuticals, Inc. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals’ Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet

  December 2, 2008

   · 

  5 min read